Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Trial details
- Registry ID
- NCT04446117
- Phase
- Phase 3
The FDA approved Abiraterone Acetate (Zytiga) on 28 Apr 2011.
Drug identity checked against registry records
Also recorded as Abiraterone; Zytiga
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCNCT04446117 | Exelixis | Phase 3 | Active not recruiting | 2024-04-19Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2011-04-28Day | Abiraterone Acetate | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA202379", "applicant_as_listed_by_fda": "JANSSEN BIOTECH", "brand_names": ["ZYTIGA"], "active_ingredients": ["ABIRATERONE ACETATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20110428", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |